Actively Recruiting
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
Led by Chinese SLE Treatment And Research Group · Updated on 2023-12-12
100
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an observational study of patients with lupus nephritis aiming to find biomarkers that can predict patients' response to immunosuppressants. We planed to collect 100 lupus nephritis patients' peripheral blood,kidney tissues and urine before and after treatment (mycophenolate mofetil or cyclophosphamide, in combination with glucocorticoids). Then multi omics analysis, including single cell RNA-seq, ATAC-seq and CITE-seq, will be performed to find new biomarkers for patients' response and prognosis.
CONDITIONS
Official Title
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 16 and 60 years
- Diagnosed with systemic lupus erythematosus (SLE) according to the 2012 SLICC classification
- Kidney biopsy classified as class III, IV, V+III, or V+IV within the past 6 months
- Kidney biopsy shows active lupus nephritis disease
- Two 24-hour urine protein tests within two weeks showing greater than 1 gram each
- Never received glucocorticoids or immunosuppressants, or received standard treatment for more than 1 month without changes
- Standard treatment includes prednisone 0-20 mg/day or equivalent glucocorticoids, and acceptable immunosuppressants within specified dose limits
- Provided informed consent
You will not qualify if you...
- Having other connective tissue or autoimmune diseases
- Having neuropsychiatric lupus, alveolar hemorrhage, retinal lesions, pulmonary arterial hypertension, or other severe organ involvement
- Pregnant or breastfeeding women
- Current infections requiring antibiotic or antiviral treatment
- Having other kidney diseases
- Platelet count less than 50 x 10^9/L
- Elevated liver enzymes (ALT or AST) greater than 1.5 times normal upper limit
- Elevated total bilirubin or blood lipid levels greater than 2 times normal upper limit
- Any other condition deemed unsuitable for study participation by the investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, China
Actively Recruiting
Research Team
X
Xinping Tian, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here